Bioprosthetic valves and atrial fibrillation: Direct anticoagulants or warfarin

The Journal of Thoracic and Cardiovascular Surgery

article

Samir R. Kapadia¹  Lars G. Svensson² 

[1] Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic;Department of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic;Aorta Center, Heart, Vascular, and Thoracic Institute, Cleveland Clinic

关键词: anticoagulation;    antithrombotic;    coagulation cascade;    stroke prevention;    TAVR;   

DOI  :  10.1016/j.jtcvs.2021.05.051

学科分类：心脏病和心血管学

来源: Mosby, Inc.

【 摘 要 】

Feature Editor's Introduction—Warfarin was first developed in the 1940s as rat poison and was clinically first used in the 1950s in humans as an anticoagulant. Since then, we have been in search of a suitable alternative that can offer our patients a more reliable and predictable physiologic effect, as well as less disruption in their day-to-day life. It was not until 2010 that dabigatran (Pradaxa, Boehringer Ingelheim, Ridgefield, Conn) was approved by the Food and Drug Administration, but was not approved for use in patients with valvular heart disease.

【 授权许可】

Unknown